Categories: Wire Stories

Akerna Announces Financial Results for Third Quarter 2022

Software revenue increases 17% for Q3 and 39% for the year-to-date

DENVER, Nov. 14, 2022 (GLOBE NEWSWIRE) — Akerna (Nasdaq: KERN), a leading enterprise software company and developer of one of the most comprehensive technology infrastructures, ecosystems, and compliance engines powering the global cannabis industry, today reported its unaudited financial results for the third quarter, ended September 30, 2022.

�We continue to focus our resources on building a stable and sustainable financial model at Akerna, and we are well-positioned for future growth,” said Jessica Billingsley, CEO of Akerna. “This is evident in our double-digit growth in reported software sales for the quarter, the implementation of aggressive cost control measures we implemented throughout the year which are tracking through the P&L, and the narrowing of our Adjusted EBITDA losses.”

“We believe that our current business units, which are supported by and consist of 75% recurring annual revenue, provide us the means to reach a point of sustained profitability at our current sales growth rate,” concluded Ms. Billingsley.

Third Quarter 2022 Financial Highlights

  • Software revenue was $5.3 million, up 17% year-over-year
  • Total revenue was $5.4 million, up 5% year-over-year
  • Gross profit of $3.4 million, or 62% of total revenues, was essentially flat with $3.2 million, or 62% of total revenues in the same period of 2021
  • Loss from operations was $0.8 million which included a $3.0 million benefit, attributable to an acquisition earn-out adjustment, compared to a loss of $3.7 million in last year’s same period
  • Net loss was $2.3 million compared to a loss of $1.5 million in last year’s third quarter
  • Adjusted EBITDA* loss was $1.4 million compared with a loss of $1.5 million for the same quarter of 2021, and compared to an Adjusted EBITDA loss of $2.1 million in the second quarter of 2022
  • Cash and restricted cash was $9.5 million as of September 30, 2022

*See “Explanation of Non-GAAP Financial Measures” below

Third Quarter 2022 Key Metrics

  • CARR of $16.9 million, up 3% year-over-year
  • Q3 software bookings of approximately $440K
  • Transaction volume up 10% sequentially
  • Average new business deal size decreased by 16% year-over-year
  • Transaction dollar amount down 10% sequentially

Other Key Developments:

  • The company continues to explore strategic and financial alternatives to strengthen its balance sheet
  • Closed an equity transaction providing net proceeds of $9.2 million on July 5, 2022
  • Announced that shareholders voted in favor of a 20-for-1 reverse stock split which was effectuated immediately thereafter in order to maintain compliance with Nasdaq listing standards

The foregoing financial results are preliminary in nature. Final financial results and other disclosures will be reported in Akerna’s quarterly report on Form 10-Q and may differ materially from the results and disclosures today due to, among other things, the completion of final review procedures, the occurrence of subsequent events or the discovery of additional information. You are encouraged to review the Form 10-Q in detail.

Conference Call Details

Akerna will host a conference call Monday, November 14, 2022, at 11:00 a.m. Eastern Time to discuss its financial results and business highlights. A question-and-answer session will follow prepared remarks. Interested parties may listen to the call by dialing:

Toll-Free: 1-877-407-3982
Toll / International: 201-493-6781
Conference ID#: 13733796

The conference call will also be available via a live, listen-only webcast and can be accessed through the Investor Relations section of Akerna’s website, https://ir.akerna.com/

To be included on the Company’s email distribution list, please sign up at https://ir.akerna.com/news-events/email-alerts

About Akerna

Akerna (Nasdaq: KERN) is an enterprise software company focused on compliantly serving the cannabis, hemp, and CBD industry. First launched in 2010, Akerna has tracked more than $30 billion in cannabis sales to date and is the first cannabis software company listed on Nasdaq. The company’s cornerstone technology, MJ Platform, one of the world’s leading cannabis infrastructure as a service platform, powers retailers, manufacturers, brands, distributors, and cultivators.

For more information, visit https://www.akerna.com/.

Forward Looking Statements

Certain statements made in this release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. Such forward-looking statements include but are not limited to statements regarding our preliminary financial results which may differ from our final financial results, our preparation for a potential post-legalization landscape, our believe enterprise capabilities, including comprehensive compliance solutions and financial reporting integrations, will become increasingly important to the future leaders of the cannabis industry and the timing for management’s conference call in relation to our quarterly results. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of significant known and unknown risks, uncertainties, assumptions, and other important factors, many of which are outside Akerna’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others that may affect actual results or outcomes, include (i) Akerna’s ability to maintain relationships with customers and suppliers and retain its management and key employees, (ii) changes in applicable laws or regulations, (iii) changes in the market place due to the coronavirus pandemic or other market factors, (iv) and other risks and uncertainties disclosed from time to time in Akerna’s filings with the U.S. Securities and Exchange Commission, including those under “Risk Factors” therein. You are cautioned not to place undue reliance on forward-looking statements. All information herein speaks only as of the date hereof, in the case of information about Akerna, or the date of such information, in the case of information from persons other than Akerna. Akerna undertakes no duty to update or revise the information contained herein. Forecasts and estimates regarding Akerna’s industry and end markets are based on sources believed to be reliable; however, there can be no assurance these forecasts and estimates will prove accurate in whole or in part.

Explanation of Non-GAAP Financial Measures

In addition to our results determined in accordance with U.S. generally accepted accounting principles (“GAAP”), we believe the following non-GAAP measures are useful in evaluating our operating performance. We use the following non-GAAP financial information to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP.

Investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool. Other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison. We attempt to compensate for these limitations by providing specific information regarding the GAAP items excluded from these non-GAAP financial measures.

Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures and not rely on any single financial measure to evaluate our business.

Adjusted EBITDA

We believe that Adjusted EBITDA, when considered with the financial statements determined in accordance with GAAP, is helpful to investors in understanding our performance and allows for comparison of our performance and credit strength to our peers. Adjusted EBITDA should not be considered alternatives to net loss as determined in accordance with GAAP as indicators of our performance or liquidity.

We define EBITDA as net loss before interest expense, provision for income taxes, depreciation and amortization. We calculate Adjusted EBITDA as EBITDA further adjusted to exclude the effects of the following items for the reasons set forth below:

  • Impairment of long-lived assets, because it’s a non-cash, non-recurring item, which effects the comparability of results of operations and liquidity;
  • Stock-based compensation expense, because this represents a non-cash charge and our mix of cash and share-based compensation may differ from other companies, which effects the comparability of results of operations and liquidity;
  • Cost incurred in connection with business combinations and mergers that are required to be expensed as incurred in accordance with GAAP, because business combination and merger related costs are specific to the complexity and size of the underlying transactions as well as the frequency of our acquisition activity these costs are not reflective of our ongoing operations;
  • Cost incurred in connection with non-recurring financing, including fees incurred as a direct result of electing the fair value option to account for our debt instruments;
  • Restructuring charges, which include costs to terminate a lease and the related write off of leasehold improvements and furniture, as we believe these costs are not representative of operating performance;
  • Gain on forgiveness of PPP loan, as this is a one-time forgiveness of debt that is not recurring across all periods and we believe inclusion of the gain is not representative of operating performance;
  • Equity in losses of investees because our share of the operations of investees is not representative of our own operating performance and may not be monetized for a number of years;
  • Changes in fair value of contingent consideration because these adjustments are not recurring across all periods and we believe these costs are not representative of operating performance; and
  • Other non-operating expenses which includes items such as a one-time gain on debt extinguishment and a one-time loss on disposal of fixed assets, which effects the comparability of results of operations and liquidity.

Related Non-GAAP Expense Measure

We reference in our earnings call non-GAAP Operating Expenses. We believe that this non-GAAP financial measure, when considered with the financial statements determined in accordance with GAAP, is helpful to management and investors in understanding our performance quarter over quarter and to the comparable quarter in our prior fiscal year by excluding the same items we exclude from EBITDA to derive Adjusted EBITDA that are included in GAAP operating expenses, as set forth above (impairment of long-lived assets, stock-based compensation expense, costs incurred with business combinations, changes in the fair value of contingent consideration, costs incurred in connection with debt issuance, restructuring costs and certain other non-operating expenses, as described above) for the same reasons stated above– principally, that these expenses are not, in management’s opinion, easily comparable across reporting periods, are not reflective of ongoing operations and/or are not representative of our operating performance.

We define non-GAAP Operating Expenses, as GAAP Operating Expenses, excluding impairment of long-lived assets, stock-based compensation expense, costs incurred with business combinations, changes in the fair value of contingent consideration, costs incurred in connection with debt issuance and restructuring costs.

This non-GAAP expense measure should not be considered an alternative to the corresponding GAAP financial measure as determined in accordance with GAAP as an indicator of our performance or liquidity. Please review the tables provided below, for a reconciliation of this non-GAAP expense measure to the corresponding GAAP financial measure.

The reconciliation of the above non-GAAP financial measures for the quarter ended September 30, 2022 are presented in the tables below. For comparative purposes, the reconciliation of these non-GAAP financial measures in the prior quarter ended June 30, 2022 are contained in our press release for that quarter dated August 10, 2022 and available in our current report on Form 8-K filed with the Securities and Exchange Commission on August 10, 2022 and available here: https://www.sec.gov/ix?doc=/Archives/edgar/data/1755953/000121390022046403/ea164161-8k_akerna.htm

Key Performance Metrics

We use several key performance metrics in this press release.

We define committed annual recurring revenue (“CARR”) as the total amount of contracted annualized recurring revenue for which clients have signed contracts as of the end of the stated period, assuming any contract that expires during the next 12 months is renewed on its existing terms. CARR includes the annualized value of contracted subscriptions, the annualized value of contracted software support services active and the annualized value of contracted consulting services at the end of a reporting period and does not include revenue reported as “Other Revenue” in our consolidated statement of operations. We are monitoring these metrics because they align with how our customers are increasingly purchasing our software solutions and how we are managing our business. The CARR metric should be viewed independently of revenue and CARR is not an indicator of future revenue.

We define software bookings as the dollar amount of new signed software contracts, the value of which will be recognized over the life of the contract. We define the average new business deal size as the average monthly recurring revenue of bookings for new customers and expansion on existing accounts in the period. We monitor growth in bookings and deal size as a near-term leading indicator of our business’s performance. Software bookings should be reviewed independently of revenue and is not an indicator of future revenue.

We define transactions as the sale of cannabis good recorded on our system and including sales between a retailer and a consumer and sales throughout the supply chain throughout the wholesale process before the consumer transaction. We define transaction dollar amount as the total dollar value of transactions that are tracked on our systems during the reported period. We define transaction numbers as the total number of transactions that are recorded on our systems during the reported period. Transaction dollar amount and transaction value do not relate to transactions by Akerna but to transactions undertaken by our clients tracked on our systems. We track transaction dollar value and transaction numbers as a long-term leading indicator of our market share. These metrics should be viewed independently of revenue and are not an indicator of future revenue.

Investor Contacts
IR@akerna.com

AKERNA CORP.
Condensed Consolidated Balance Sheets
(unaudited)
  September 30,   December 31,
    2022       2021  
Assets      
Current assets      
Cash $ 2,490,662     $ 13,934,265  
Restricted cash   7,008,261       508,261  
Accounts receivable, net   1,371,133       1,403,774  
Prepaid expenses & other current assets   2,330,032       2,383,764  
Total current assets   13,200,088       18,230,064  
 
Fixed assets, net   124,760       153,151  
Investment, net   226,101       226,101  
Capitalized software, net   6,009,163       7,311,676  
Intangible assets, net   17,005,584       21,609,794  
Goodwill   9,025,589       46,942,681  
Other noncurrent assets         9,700  
Total assets $ 45,591,285     $ 94,483,167  
 
Liabilities and equity      
Current liabilities      
Accounts Payable, accrued expenses and other current liabilities $ 4,630,681     $ 6,063,520  
Contingent consideration payable   3,300,000       6,300,000  
Deferred revenue   2,151,235       3,543,819  
Current portion of long-term debt   9,900,000       13,200,000  
Derivative liability   9,025       63,178  
Total current liabilities   19,990,941       29,170,517  
 
Deferred revenue, noncurrent   499,206       582,676  
Long-term debt, noncurrent   4,575,000       4,105,000  
Deferred income taxes   431,453       675,291  
Total liabilities   25,496,600       34,533,484  
Equity      
Preferred stock          
Special voting preferred stock   2,227,619       2,366,038  
Common stock   402       155  
Additional paid-in capital   159,841,800       146,030,203  
Accumulated other comprehensive income   356,028       61,523  
Accumulated deficit   (142,331,164 )     (88,508,236 )
Total equity   20,094,685       59,949,683  
Total liabilities and equity $ 45,591,285     $ 94,483,167  
 

AKERNA CORP.
Condensed Consolidated Statements of Operations
(unaudited)
               
  For the Three Months   For the Nine Months
  Ended September 30,   Ended September 30,
    2022       2021       2022       2021  
Revenue              
Software $ 5,326,830     $ 4,557,960     $ 17,756,272     $ 12,809,841  
Consulting   76,500       551,402       618,809       1,135,033  
Other revenue   9,472       26,140       74,443       111,540  
Total revenue   5,412,802       5,135,502       18,449,524       14,056,414  
Cost of revenue   2,051,862       1,971,382       6,091,511       5,339,929  
Gross profit   3,360,940       3,164,120       12,358,013       8,716,485  
Operating expenses              
Research and development   1,374,133       1,566,478       5,240,922       4,517,836  
Sales and marketing   1,882,980       2,002,461       8,304,411       5,564,519  
General and administrative   1,823,076       2,077,474       6,812,617       8,306,417  
Depreciation and amortization   2,118,739       1,238,420       6,094,963       3,605,435  
Impairment of long-lived assets               39,600,587        
Changes in fair value of contingent consideration   (3,000,000 )           (3,000,000 )      
Total operating expenses   4,198,928       6,884,833       63,053,500       21,994,207  
Loss from operations   (837,988 )     (3,720,713 )     (50,695,487 )     (13,277,722 )
Other income (expense)              
Interest income (expense)   (396,022 )     (238,283 )     (609,746 )     (1,175,789 )
Change in fair value of convertible notes   (1,113,000 )     (23,227 )     (2,840,000 )     (2,030,904 )
Change in fair value of warrant liability   2,256       194,046       54,153       151,175  
Gain on forgiveness of PPP Loan         2,234,730             2,234,730  
Other expense                     243  
Total other income (expense)   (1,506,766 )     2,167,266       (3,395,593 )     (820,545 )
 
Net loss before income tax expense   (2,344,754 )     (1,553,447 )     (54,091,080 )     (14,098,267 )
Income tax expense   40,666             268,152       (10,570 )
Equity in losses of investee                     (7,564 )
 
Net loss $ (2,304,088 )   $ (1,553,447 )   $ (53,822,928 )   $ (14,116,401 )
 
Basic and diluted weighted average common stock outstanding   3,883,847       1,322,122       2,421,262       1,215,626  
Basic and diluted net loss per share $ (0.59 )   $ (1.17 )   $ (22.23 )   $ (11.62 )
               

AKERNA CORP.
Condensed Consolidated Statements of Cash Flows
(unaudited)
  For the Nine Months
  Ended September 30,
Cash flows from operating activities      
Net loss $ (53,822,928)   $ (14,116,401)
Adjustments to reconcile net loss to net cash used in operating activities:    
Equity in losses of investment   7,564
Contingent consideration adjustment (3,000,000)  
Bad debt expense 271,474   254,029
Stock-based compensation expense, net 697,377   1,584,751
Loss on write-off of fixed assets   1,045,179
Gain on forgiveness of PPP Loan   (2,234,730)
Impairment of long-lived assets 39,600,587  
Amortization of deferred contract cost 275,949   356,528
Non-cash interest expense 183,723   1,161,393
Depreciation and amortization 6,094,963   3,605,435
Foreign currency loss (gain) 4,718   21,496
Change in fair value of convertible notes 2,840,000   2,030,904
Change in fair value of derivative liability (54,153)   (151,175)
Change in operating assets and liabilities:      
Accounts receivable, net (313,176)   462,482
Prepaid expenses and other current and noncurrent assets (215,228)   66,246
Accounts payable, accrued expenses and other accrued liabilities (1,356,709)   1,756,671
Deferred income tax liabilities (243,838)  
Deferred revenue (1,413,665)   (927,916)
Net cash used in operating activities (10,450,906)   (5,077,544)
Cash flows from investing activities      
Developed software additions (3,324,029)   (3,354,453)
Fixed asset additions (27,383)   (11,535)
Cash returned from business combination working capital settlement 400,000  
Net cash used in investing activities (2,951,412)   (3,365,988)
Cash flows from financing activities      
Value of shares withheld related to tax withholdings (13,167)   (437,554)
Proceeds from unit and pre-funded unit offering, net 9,178,961  
Principal payments of convertible notes (1,432,273)   (1,164,706)
Proceeds from the ATM offering program, net 761,178   1,828,116
Net cash provided by financing activities 8,494,699   225,856
Effect of exchange rate changes on cash and restricted cash (35,984)   (5,915)
Net change in cash and restricted cash (4,943,603)   (8,223,591)
Cash and restricted cash – beginning of period 14,442,526   18,340,640
Cash and restricted cash – end of period $ 9,498,923   $ 10,117,049
       

AKERNA CORP.
The Reconciliation of Net Loss to EBITDA and Adjusted EBITDA is as follows:
(unaudited)
               
  Three Months Ended September 30,   Nine Months Ended September 30, 2022
    2022       2021       2022       2021  
Net loss $ (2,304,088 )   $ (1,553,447 )   $ (53,822,928 )   $ (14,116,401 )
Adjustments:              
Interest expense (income)   396,022       238,283       609,746       1,175,789  
Change in fair value of convertible notes   1,113,000       23,227       2,840,000       2,030,904  
Change in fair value of derivative liability   (2,256 )     (194,046 )     (54,153 )     (151,175 )
Income tax expense   (40,666 )           (268,152 )     10,570  
Depreciation and amortization   2,118,739       1,238,420       6,094,963       3,605,435  
EBITDA $ 1,280,751     $ (247,563 )   $ (44,600,524 )   $ (7,444,878 )
Impairment of long-lived assets               39,600,587        
Stock-based compensation expense   203,384       477,625       648,439       1,502,339  
Business combination and merger related costs         182,631       5,425       290,357  
Non-recurring financing fees   71,192       280,768       424,675       410,362  
Restructuring charges   59,094             1,127,038       2,453,776  
Changes in fair value of contingent consideration   (3,000,000 )           (3,000,000 )      
Gain on forgiveness of PPP Loan         (2,234,730 )           (2,234,730 )
Equity in losses of investee                     7,564  
Adjusted EBITDA $ (1,385,579 )   $ (1,541,269 )   $ (5,794,360 )   $ (5,015,210 )
               

AKERNA CORP.
The Reconciliation of Operating Expenses to non-GAAP Operating Expenses is as follows:
(unaudited)
               
  Three Months Ended September 30,   Nine Months Ended September 30, 2022
    2022     2021     2022     2021
Operating Expenses $ 4,198,928     $ 6,884,833   $ 63,053,500     $ 21,994,207
Adjustments:              
Depreciation and amortization   2,118,739       1,238,420     6,094,963       3,605,435
Stock-based compensation expense   203,384       477,625     648,439       1,502,339
Business combination and merger related costs         182,631     5,425       290,357
Non-recurring financing fees   71,192       280,768     424,675       410,362
Restructuring charges   59,094           1,127,038       2,453,776
Impairment of long-lived assets             39,600,587      
Changes in fair value of contingent consideration   (3,000,000 )         (3,000,000 )    
Non-GAAP Operating Expenses $ 4,746,519     $ 4,705,389   $ 18,152,373     $ 13,731,938
               

AKERNA CORP.
The Reconciliation of Product Development Expenses to non-GAAP Product Development Expenses is as follows:
(unaudited)
               
  Three Months Ended September 30,   Nine Months Ended September 30, 2022
  2022   2021   2022   2021
Product development expense $ 1,374,133   $ 1,566,478   $ 5,240,922   $ 4,517,836
Stock-based compensation expense   76,432     166,758     265,063     574,665
Restructuring charges   58,584         226,711    
Non-GAAP product development expense $ 1,239,117   $ 1,399,720   $ 4,749,148   $ 3,943,171
               

AKERNA CORP.
The Reconciliation of Sales and Marketing Expenses to non-GAAP Sales and Marketing Expenses is as follows:
(unaudited)
               
  Three Months Ended September 30,   Nine Months Ended September 30, 2022
  2022   2021     2022     2021
Sales and marketing expense $ 1,882,980   $ 2,002,461   $ 8,304,411     $ 5,564,519
Stock-based compensation expense   13,502     123,204     (31,580 )     366,790
Non-recurring financing fees   161         161      
Restructuring charges           277,049      
Non-GAAP product sales and marketing $ 1,869,317   $ 1,879,257   $ 8,058,781     $ 5,197,729
               

AKERNA CORP.
The Reconciliation of General and Administrative Expenses to non-GAAP General and Administrative Expenses is as follows:
(unaudited)
               
  Three Months Ended September 30,   Nine Months Ended September 30, 2022
  2022   2021   2022   2021
General and administrative expense $ 1,823,076   $ 2,077,474   $ 6,812,617   $ 8,306,417
Stock-based compensation expense   104,457     146,989     393,047     450,466
Business combination and merger related costs       182,631     5,425     290,357
Non-recurring financing fees   71,031     280,768     424,514     410,362
Restructuring charges   510         604,633     2,454,019
Non-GAAP general and administrative expense $ 1,647,078   $ 1,467,086   $ 5,384,998   $ 4,701,213
               

 

 

Alex

Recent Posts

China Focus: Technology sows seeds of hope in combating desertification

HOHHOT, CHINA - Media OutReach Newswire - 23 December 2024 - China's National Forestry and…

4 hours ago

Novautek Honored with the “Outstanding SME ESG and Business Performance Award”

HONG KONG SAR - EQS Newswire - 23 December 2024 - Novautek Autonomous Driving Limited…

7 hours ago

V-GREEN and Xanh SM Indonesia sign MoU with Lippo for comprehensive green ecosystem in Indonesia

JAKARTA, INDONESIA - Media OutReach Newswire - 23 December 2024 - V-GREEN and PT Xanh…

7 hours ago

Molex Anticipates Steady Growth in High-Speed Connectivity in 2025, Driving Electronics Design Innovations Across Diverse Industry Sectors

Increase in opportunities predicted for high-speed optical transceivers and miniaturized connectivity solutions to address data-intensive…

9 hours ago

Celebrating 25 Years of Excellence: DYXnet Embarks the New Chapter of Digital Transformation

HONG KONG SAR - Media OutReach Newswire - 23 December 2024 - DYXnet, a wholly-owned…

9 hours ago

The Top 10 Best Places to Work in Egypt for 2024 revealed

CAIRO, EGYPT - Media OutReach Newswire - 23 December 2024 - Eand, Novo Nordisk, BSH,…

12 hours ago